

## Highlights of This Issue 631

## REVIEW

- 633** Efficacy of Hedgehog Pathway Inhibitors in Basal Cell Carcinoma  
Nicole Basset-Seguín, Hayley J. Sharpe, and Frederic J. de Sauvage

## SMALL MOLECULE THERAPEUTICS

- 642** Validation of the Hsp70–Bag3 Protein–Protein Interaction as a Potential Therapeutic Target in Cancer  
Xiaokai Li, Teresa Colvin, Jennifer N. Rauch, Diego Acosta-Alvear, Martin Kampmann, Bryan Dunyak, Byron Hann, Blake T. Aftab, Megan Murnane, Min Cho, Peter Walter, Jonathan S. Weissman, Michael Y. Sherman, and Jason E. Gestwicki
- 649** The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents  
Jude Canon, Tao Osgood, Steven H. Olson, Anne Y. Saiki, Rebecca Robertson, Dongyin Yu, John Eksterowicz, Qiuping Ye, Lixia Jin, Ada Chen, Jing Zhou, David Cordover, Stephen Kaufman, Richard Kendall, Jonathan D. Oliner, Angela Coxon, and Robert Radinsky
- 659** Protease-Activated Pore-Forming Peptides for the Treatment and Imaging of Prostate Cancer  
Aaron M. LeBeau and Samuel R. Denmeade

## LARGE MOLECULE THERAPEUTICS

- 669** Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance  
Mikkel W. Pedersen, Helle J. Jacobsen, Klaus Koefoed, Anna Dahlman, Ida Kjær, Thomas T. Poulsen, Per-Johan Meijer, Lars S. Nielsen, Ivan D. Horak, Johan Lantto, and Michael Kragh
- 681** A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies  
Xuejun Fan, Randall J. Brezski, Hui Deng, Pooja M. Dhupkar, Yun Shi, Anneliese Gonzalez, Songlin Zhang, Michael Ryczyn, William R. Strohl, Robert E. Jordan, Ningyan Zhang, and Zhiqiang An

- 692** The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers



Miranda M.C. van der Lee, Patrick G. Groothuis, Ruud Ubink, Monique A.J. van der Vleuten, Tanja A. van Achterberg, Eline M. Loosveld, Désirée Damming, Daniëlle C.H. Jacobs, Myrthe Rouwette, David F. Egging, Diels van den Dobbelen, Patrick H. Beusker, Peter Goedings, Gijs F.M. Verheijden, Jacques M. Lemmens, Marco Timmers, and Wim H.A. Dokter

## CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 704** Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1  
Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi, Toshihiko Fujii, Yasuko Satoh, Nobuya Ishii, and Masahiro Aoki
- 713** Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer  
David T. Hoang, Lei Gu, Zhiyong Liao, Feng Shen, Pooja G. Talati, Mateusz Koptyra, Shyh-Han Tan, Elyse Ellsworth, Shilpa Gupta, Heather Montie, Ayush Dagvadorj, Saija Savolainen, Benjamin Leiby, Tuomas Mirtti, Diane E. Merry, and Marja T. Nevalainen
- 727** Histone Deacetylase 6 Represents a Novel Drug Target in the Oncogenic Hedgehog Signaling Pathway  
Pavan Kumar Dhanyamraju, Philipp Simon Holz, Florian Finkernagel, Volker Fendrich, and Matthias Lauth
- 740** CD30 Is a Potential Therapeutic Target in Malignant Mesothelioma  
Snehal Dabir, Adam Kresak, Michael Yang, Pingfu Fu, Gary Wildey, and Afshin Dowlati
- 747** Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78  
Lihong Mo, Robin E. Bachelder, Margaret Kennedy, Po-Han Chen, Jen-Tsan Chi, Andrew Berchuck, George Cianciolo, and Salvatore V. Pizzo

# Table of Contents

**757** **Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts**



Verena Paulitschke, Walter Berger, Philipp Paulitschke, Elisabeth Hofstätter, Bernhard Knapp, Ruth Dingelmaier-Hovorka, Dagmar Födinger, Walter Jäger, Thomas Szekeres, Anastasia Meshcheryakova, Andrea Bileck, Christine Pirker, Hubert Pehamberger, Christopher Gerner, and Rainer Kunstfeld

**769** **Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide *In Vivo***

Valerie N. Barton, Nicholas C. D'Amato, Michael A. Gordon, Hanne T. Lind, Nicole S. Spoelstra, Beatrice L. Babbs, Richard E. Heinz, Anthony Elias, Paul Jedlicka, Britta M. Jacobsen, and Jennifer K. Richer

**779** **Notch Reporter Activity in Breast Cancer Cell Lines Identifies a Subset of Cells with Stem Cell Activity**

Rosemarie C. D'Angelo, Maria Ouzounova, April Davis, Daejin Choi, Stevie M. Tchienkam, Gwangil Kim, Tahra Luther, Ahmed A. Quraishi, Yasin Senbabaoglu, Sarah J. Conley, Shawn G. Clouthier, Khaled A. Hassan, Max S. Wicha, and Hasan Korkaya

**788** **Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation**

Huai-Qiang Ju, Takeshi Gocho, Mitzi Aguilar, Min Wu, Zhuo-Nan Zhuang, Jie Fu, Katsuhiko Yanaga, Peng Huang, and Paul J. Chiao

**799** **Inhibition of p70S6K1 Activation by Pdc4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells**

Yan Zhang, Qing Wang, Li Chen, and Hsin-Sheng Yang

**810** **Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells**

Yu-Chieh Tsai, Pei-Yin Ho, Kai-Yuan Tzen, Tsung-Fan Tuan, Wei-Lin Liu, Ann-Lii Cheng, Yeong-Shiau Pu, and Jason Chia-Hsien Cheng

## COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

**821** **Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy**

Wendy Onstenk, Jaco Kraan, Bianca Mostert, Mieke M. Timmermans, Ayoub Charehbili, Vincent T.H.B.M. Smit, Judith R. Kroep, Johan W.R. Nortier, Saskia van de Ven, Joan B. Heijns, Lonneke W. Kessels, Hanneke W.M. van Laarhoven, Monique M.E.M. Bos, Cornelis J.H. van de Velde, Jan W. Gratama, Anieta M. Sieuwerts, John W.M. Martens, John A. Foekens, and Stefan Sleijfer

**828** **A Comprehensive Expression Analysis of Cancer Testis Antigens in Head and Neck Squamous Cell Carcinoma Reveals *MAGEA3/6* as a Marker for Recurrence**

Fernando Tadeu Zamunér, Bruno Takao Real Karia, Cleyton Zanardo de Oliveira, Carlos Roberto dos Santos, André Lopes Carvalho, and André Luiz Vettore

## MODELS AND TECHNOLOGIES

**835** **A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus**

Yanchun Ma, Sijie Hao, Shuwen Wang, Yuanjun Zhao, Bora Lim, Ming Lei, David J. Spector, Wafik S. El-Deiry, Si-yang Zheng, and Jiyue Zhu

## CORRECTION

**844** **Correction: MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas**



AC icon indicates Author Choice


For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)



# Table of Contents

## ABOUT THE COVER

The FDA-approved BRAF inhibitor vemurafenib achieves outstanding clinical response rates in melanoma patients, but early resistance is common. Understanding of the pathomechanisms of drug resistance and identification of effective therapeutic alternatives are key challenges for melanoma research. Despite intensive efforts, the breakthrough to understand and prevent resistance to RAF inhibition has not been achieved. This might be due to the plasticity and heterogeneity of melanoma, which allow the tumor cells to adapt to biological processes. Proteomics facilitate a broad insight into the active, complex pathomechanisms. The authors' proteome data demonstrate in a melanoma cell model with acquired resistance that vemurafenib resistance can be characterized by enhanced expression of the lysosomal compartment, enhanced cell adhesion, and by epithelial-mesenchymal transition (EMT) associated with an invasive, more aggressive phenotype. The typical morphology of EMT was demonstrated using a scanning electron microscopy. As visualized in the cover, the vemurafenib-sensitive cells had a ball-like structure and were smaller, whereas sprouted cells were almost exclusively found in the resistant cell lines. For details, see the article by Paulitschke and colleagues on page 757.



# Molecular Cancer Therapeutics

**14 (3)**

*Mol Cancer Ther* 2015;14:631-844.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/14/3>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/14/3>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.